Summary
CVS Health Corporation (CVS) announced on December 21, 2020, the early results and upsize of its previously launched cash tender offers for its outstanding senior notes. The company increased the total aggregate maximum amount for these tender offers to $4.5 billion from $4.0 billion, indicating a proactive approach to managing its debt obligations. This upsize reflects CVS Health's commitment to optimizing its capital structure by repurchasing a larger principal amount of its senior notes. The company specifically increased the maximum amounts allocated to the 2025 and 2028 Notes tender offers. With the aggregate maximum amount now set at $4.5 billion, CVS Health anticipates accepting all validly tendered notes by the early settlement date of December 22, 2020, effectively concluding these particular tender offers shortly after this announcement.
Key Highlights
- 1CVS Health upsized its cash tender offers for outstanding senior notes to a total aggregate maximum amount of $4.5 billion, an increase from the previously announced $4.0 billion.
- 2The company increased the maximum principal amount to be repurchased for the 2025 Notes to $1,049,919,000 and for the 2028 Notes to $1,950,081,000.
- 3The tender offers cover various series of senior notes due in 2023, 2025, and 2028, with specific maximum amounts allocated to each.
- 4CVS Health expects to accept for purchase the full $4.5 billion Aggregate Maximum Amount of Notes.
- 5The early settlement date for notes validly tendered and accepted is December 22, 2020.
- 6No additional notes are expected to be purchased in these tender offers after December 22, 2020, given the expected acceptance of the full amount.
- 7The filing includes press releases detailing the early results and pricing of these upsized tender offers.